Opioid Receptor Kappa 1 (OPRK1) Antibody

Este producto es parte de OPR - Opioid Receptor
Product Graph
416€ (200 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Opioid Receptor Kappa 1 (OPRK1) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx431478
tested applications
P-ELISA, WB

Description

OPRK1 Antibody is a Goat Polyclonal antibody against OPRK1.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Opioid Receptor Kappa 1 (OPRK1)
Host
Goat
Reactivity
Human
Recommended Dilution
P-ELISA: 1/16000. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Unconjugated
Isotype
IgG
Purification
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Size 1
200 µl
Form
Liquid
Tested Applications
P-ELISA, WB
Buffer
Tris saline, pH 7.3, containing 0.02% sodium azide and 0.5% bovine serum albumin.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
Gene ID
4986, 18387, 29335
NCBI Accession
NP_000903.2
Alias
OPRK1,KOR-1,Kappa receptor,OP2,KOP,KOPr,OPRK, K-OR-1
Background
Antibody anti-OPRK1
Status
RUO
Note
Concentration: 0.5 mg/ml -

Descripción

OPRK1, or the kappa-opioid receptor, is a G protein-coupled receptor (GPCR) that binds endogenous opioid peptides such as dynorphins. It is widely expressed in the central nervous system, particularly in regions like the spinal cord, hypothalamus, and limbic system, where it modulates pain, stress responses, and mood. OPRK1 couples to Gi/o proteins, leading to inhibition of adenylate cyclase, decreased cAMP production, and reduced neurotransmitter release. Activation of OPRK1 produces analgesia, particularly in visceral and spinal pain pathways, and induces dysphoria and sedation. OPRK1 also plays a key role in stress-induced behaviors, drug addiction, and depression, where its activation can reduce dopamine release and inhibit reward pathways. Dysregulation of OPRK1 signaling contributes to chronic pain, addiction, and stress-related disorders. Kappa-opioid receptor agonists are being developed as non-addictive analgesics, while antagonists are under investigation for treating mood disorders, addiction, and stress resilience, positioning OPRK1 as a dual therapeutic target.

Related Products

abx005794

Opioid Receptor Kappa 1 (OPRK1) Antibody

OPRK1 Antibody is a Rabbit Polyclonal Antibody against OPRK1.

Ver Producto
abx015393

Opioid Receptor Kappa 1 (OPRK1) Antibody

Rabbit polyclonal antibody against OPRK1 protein. Immunogen region is C-terminal.

Ver Producto
abx031462

Opioid Receptor Kappa 1 (OPRK1) Antibody

Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Receptor for dynorphins. May play a role in arousal and regulation of autonomic and neuroendocrine functions.

Ver Producto